Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Buccisano

Showing results (1-10 of 143) with videos related to

Pageof 15
Sort By:
Current Opinion in Hematology|December 9, 2016
Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?Francesco Buccisano, Roland B Walter
Current Hematologic Malignancy Reports|October 14, 2017
The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid LeukemiaFrancesco Buccisano, Christopher S Hourigan, Roland B Walter
Best Practice & Research. Clinical Haematology|September 15, 2010
Cord blood transplantation in adults with acute myeloid leukaemiaWilliam Arcese, Francesco Buccisano, Raffaella Cerretti, et al.
Journal of Cancer Research and Clinical Oncology|May 29, 2026
Diving into the transcriptional landscape of leukemic stem cells in acute myeloid leukemia at single-cell resolutionZuzanna Rzetelska, Lidia Gil, Francesco Buccisano, et al.
Cancers|June 29, 2018
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid LeukemiaFrancesco Buccisano, Richard Dillon, Sylvie D Freeman, et al.
Cytometry. Part B, Clinical Cytometry|June 30, 2020
The ISCCA flow protocol for the monitoring of anti-CD20 therapies in autoimmune disordersArianna Gatti, Francesco Buccisano, Maria T Scupoli, et al.
Cancers|May 25, 2024
Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2Pau Montesinos, Francesco Buccisano, Thomas Cluzeau, et al.
Cancer Treatment Reviews|October 19, 2007
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemiaRoberto Stasi, Maria Laura Evangelista, Francesco Buccisano, et al.
Current Opinion in Oncology|October 1, 2025
Measurable residual disease as an actionable biomarker in acute myeloid leukemia. Ready or not?Francesco Buccisano, Raffaele Palmieri, Federico Moretti, et al.
Current Opinion in Pharmacology|May 16, 2025
Fitness in acute myeloid leukemia, state of the art and future directionsRaffaele Palmieri, Luca Maurillo, Maria Ilaria Del Principe, et al.
Pageof 15

Showing results (1-10 of 143) with videos related to

Sort By:
Pageof 15
Current Opinion in Hematology|December 9, 2016
Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?Francesco Buccisano, Roland B Walter
Current Hematologic Malignancy Reports|October 14, 2017
The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid LeukemiaFrancesco Buccisano, Christopher S Hourigan, Roland B Walter
Best Practice & Research. Clinical Haematology|September 15, 2010
Cord blood transplantation in adults with acute myeloid leukaemiaWilliam Arcese, Francesco Buccisano, Raffaella Cerretti, et al.
Journal of Cancer Research and Clinical Oncology|May 29, 2026
Diving into the transcriptional landscape of leukemic stem cells in acute myeloid leukemia at single-cell resolutionZuzanna Rzetelska, Lidia Gil, Francesco Buccisano, et al.
Cancers|June 29, 2018
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid LeukemiaFrancesco Buccisano, Richard Dillon, Sylvie D Freeman, et al.
Cytometry. Part B, Clinical Cytometry|June 30, 2020
The ISCCA flow protocol for the monitoring of anti-CD20 therapies in autoimmune disordersArianna Gatti, Francesco Buccisano, Maria T Scupoli, et al.
Cancers|May 25, 2024
Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2Pau Montesinos, Francesco Buccisano, Thomas Cluzeau, et al.
Cancer Treatment Reviews|October 19, 2007
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemiaRoberto Stasi, Maria Laura Evangelista, Francesco Buccisano, et al.
Current Opinion in Oncology|October 1, 2025
Measurable residual disease as an actionable biomarker in acute myeloid leukemia. Ready or not?Francesco Buccisano, Raffaele Palmieri, Federico Moretti, et al.
Current Opinion in Pharmacology|May 16, 2025
Fitness in acute myeloid leukemia, state of the art and future directionsRaffaele Palmieri, Luca Maurillo, Maria Ilaria Del Principe, et al.
Pageof 15